Published Date: 27 Jan 2025
Labels highlighting the risk of cancer can shift behavior
Read Full NewsTest your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on diagnosing parasomnias!
Late-breaking data from the 2026 ACTRIMS Forum showed that bazedoxifene acetate failed to improve remyelination outcomes in midlife women with relapsing MS, despite a favorable safety profile.
A nurse practitioner at the Rocky Mountain MS Clinic discussed emerging therapeutics, evolving management strategies, and unmet needs in multiple sclerosis, specifically in women’s health.
The FDA has granted priority review to Takeda’s new drug application for oveporexton, an orexin receptor 2-selective agonist, for narcolepsy type 1, with a PDUFA date in the third quarter of 2026.
Paul Nghiem highlights several key takeaways from his talk on cutaneous oncology, touching on various advances in skin cancer management.
VALIANT: Verekitug Reduces Average Annual Asthma Flare-Ups in Phase 2 Trial
REZOLVE-AD: Rezpegaldesleukin Improves Symptoms of Atopic Dermatitis
1.
The FDA approves Enhertu for HER2-positive cancers, regardless of tumor type.
2.
Advanced Solid Tumors May Benefit from Investigative Immunotherapy Combo.
3.
I Understand Why Defense Secretary Austin Kept His Prostate Cancer Quiet.
4.
Alcohol Causes Cancer. We Should Be Drinking Less.
5.
Efanesoctocog Alfa Prevented Bleeding in Kids With Severe Hemophilia A
1.
Thyroid Cancer and Insulin Resistance: Unraveling the Complex Interplay for Better Patient Outcomes
2.
Decoding the Padua Score to Prevent Blood Clots in High-Risk Patients
3.
Improving TIVAP Use: Review of Standardization and Optimization Practices
4.
Liquid Biopsies Unveiling the Future of Precision Cancer Management by 2025
5.
Liquid Biopsies in Hematology: A Window into the Disease
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Understanding Early Relapse in B-cell ALL: Rates, Risks, and Common Sites
2.
Post Progression Approaches After First-line Third-Generaion ALK Inhibitors
3.
Targeting Oncologic Drivers: A New Approach to Lung Cancer Treatment
4.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part I
5.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VIII
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation